SUTRO BIOPHARMA, INC. 8K

Sutro Biopharma reported second quarter 2026 results, highlighted encouraging early Phase 1 data for STRO-004 and upcoming milestones for STRO-006 and STRO-227, noted progress under its Astellas collaboration, and disclosed a strengthened cash position expected to fund operations into at least Q2 2028 despite ongoing net losses.

On August 12, 2026, Sutro Biopharma, Inc. reported its financial results for the quarter ended June 30, 2026 and provided a business update highlighting encouraging early safety, tolerability, pharmacokinetics, and clinical activity data from its ongoing U.S.-only Phase 1 STRIVE-01 study of STRO-004, including multiple partial responses across several solid tumor types and dose optimization between 4-5 mg/kg with no defined maximum tolerated dose to date. The company also outlined near-term pipeline milestones, including initiation of a Phase 1 trial for STRO-006 in the third quarter of 2026 and an IND filing for the dual-payload ADC STRO-227 in 2026, as well as continued progress and a recent $10 million milestone under its Astellas dual-payload iADC collaboration. Financially, Sutro reported cash, cash equivalents and marketable securities of $164.3 million as of June 30, 2026, expected to fund operations into at least the second quarter of 2028, quarterly revenue of $9.8 million largely from Astellas collaboration activities, and a net loss of $38.5 million for the quarter, alongside a significant deferred royalty obligation reflected on its balance sheet.

Filing Facts

CIK

1382101

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-345733

Alert Tier

6